How a consultant converts patient panel, payer mix, and provider dependency into a lender-grade projection for SBA, USDA, and conventional medical and dental financing — in the safest common asset class in small business lending, where the real credit risk is not the market but the person performing the production.
The safest asset class, and why that changes the assignment
Healthcare and social assistance accounts for roughly 25,600 SBA 7(a) originations over the last five fiscal years and about $16 billion in approvals — the fourth-largest sector in the programme.
It is also, on seasoned loss experience, the second-safest. Health care charge-off rates run around 4.2%, behind only agriculture at roughly 3.3%, and well below the 6.9% national average across all industries. Dental offices specifically show expected loss — charge-off frequency multiplied by loss severity — of roughly 1.5%, among the lowest of any property type in the programme.
That has a direct consequence for the consultant's work. In most asset classes the central question is whether the business will survive. Here it usually will. The demand is durable, the revenue is recurring, and the failure rate is low.
So the analysis moves elsewhere. In medical and dental, three questions carry the credit, and none of them is about market demand:
Provider dependency. The practice's production is generated by identifiable individuals. What happens when one of them leaves?
Payer mix. Two practices with identical patient volume and identical procedure mix can collect materially different revenue depending on who is paying.
Panel transferability. In an acquisition, will the patients stay after the seller does not?
A feasibility study for a dental or medical practice that spends its length establishing that people in the trade area need healthcare has answered a question nobody was asking.
What the 2026 acquisition market looks like
Most medical and dental financing is acquisition financing, and the market a buyer is entering has changed materially.
Consolidation is well advanced. Dental service organisations completed roughly 525 transactions in the last twelve months and now own approximately 24% of all US practices. Around 69% of DSO groups report planning increased acquisition activity.
Institutional capital sets the price at the top of the market. DSO buyers typically pay 6x to 8x EBITDA, with well-prepared larger practices reaching 6.5x to 9.0x on adjusted EBITDA. Independent buyer transactions range more widely — roughly 4x to 12x depending on fundamentals — and solo or small group practices commonly trade at 65% to 85% of trailing twelve-month collections, or roughly 3.5x to 6.5x EBITDA.
A retirement wave is supplying the market. Roughly 41,700 dentists hold an active NPI but no longer practise, and the transition pipeline reflects it.
SBA is the dominant financing structure below $5 million. Practice-specific lenders — Live Oak, Bank of America Practice Solutions, US Bank Practice Finance, Provide, Huntington — account for the large majority of acquisitions under that threshold. One lender alone has represented roughly 31.6% of dental dollar volume in recent years.
Current pricing. SBA 7(a) caps at $5 million and prices around Prime plus 2.25% to 2.75%, producing blended coupons in the high nines to low tens with Prime at 7.50%. A typical first-time buyer contributes a 10% equity injection with a 5% to 10% seller note on standby, and total cash at close on a $1 million to $2 million enterprise value transaction runs roughly $50,000 to $200,000.
Post-close debt service commonly consumes 25% to 40% of free cash flow.
That last figure is the one that should govern the consultant's model. It is not a comfortable margin, and it means the analysis has to be right about production and collections rather than approximately right.
Provider dependency: the central credit risk
This is where a medical or dental feasibility study earns its fee, and where generic commercial analysis fails completely.
A practice is not a building with a business inside it. The production is performed by named clinicians, and their departure removes the revenue.
The market prices this explicitly. Practices where the owner performs 90% or more of production experience valuation reductions of roughly 10% to 20% relative to comparable practices with distributed production. That discount exists because the buyer is acquiring a revenue stream that walks out of the building on closing day.
What the consultant must establish:
Production by provider. What share of collections is generated by the departing owner, by associates, and by hygiene. A practice where the owner produces 55% and two associates produce the balance is a fundamentally different acquisition from one where the owner produces 95%.
Hygiene production as a proportion of total. Hygiene revenue is recurring, systematised and does not depend on the departing dentist. A strong hygiene programme is both a valuation driver and a genuine risk mitigant, and it should be quantified rather than mentioned.
Associate arrangements and their durability. Are associates employed or contracted, are they under restrictive covenants, and are those covenants enforceable in that state? Non-compete enforceability varies substantially by jurisdiction and is not a detail — it determines whether the associate production being purchased can walk across the street.
The transition plan. How long the seller stays, in what capacity, under what compensation, and with what obligations. A ninety-day handover on a 90%-owner-production practice is not a transition; it is a hope.
The buyer's own production capacity. A first-time buyer with three to seven years of clinical experience acquiring a practice built on the seller's thirty-year reputation has to be able to produce at the level the model assumes. This is a management-feasibility question with direct financial consequences and it should be addressed explicitly rather than assumed.
Payer mix: where identical practices diverge
Two practices in the same market, seeing the same number of patients, performing the same procedures, can collect materially different revenue. The variable is payer mix.
Fee-for-service collections realise the practice's own fee schedule. Practices with FFS-dominant mixes command premium valuations for exactly this reason.
PPO participation trades volume for discounted fee schedules, and the discount varies by plan and by contract. Two PPO-heavy practices are not comparable unless their specific contracts are.
Medicaid participation typically carries the lowest reimbursement per procedure, offset by volume and, in some markets, by being the only accessible provider.
Capitation arrangements shift risk to the practice entirely.
What the consultant does: establishes collections by payer category, the write-off percentage against gross production for each, and the concentration risk in any single plan. A practice deriving 40% of collections from one PPO contract has a specific and identifiable exposure if that contract is renegotiated.
This is also where consolidation has a structural effect worth naming. DSO-affiliated practices negotiate insurance contracts at scale, which produces a genuine margin advantage over independents in the same market. An independent buyer's projection should not assume it will achieve reimbursement rates available to a group with fifty locations.
Panel transferability
In an acquisition, the consultant is assessing whether the patient base survives the ownership change.
Active patient count matters more than total records. The relevant number is patients seen within the last eighteen months, not everyone who has ever attended.
Recall and reappointment rates indicate whether the practice has systems or merely a following. A practice with an 80% reappointment rate has infrastructure; one at 45% has a personality.
New patient flow and its sources — referral, insurance directory, online, physician referral for specialty practices. A practice dependent on the departing owner's professional referral network is buying relationships that may not transfer.
Geographic concentration of the panel. Patients who travel twenty minutes for a specific dentist behave differently on transition from patients attending the nearest convenient practice.
Specialty referral patterns, for practices dependent on them. An oral surgery or endodontic practice built on referrals from general dentists who trained with the seller is a different credit from one receiving referrals institutionally.
What the consultant does for a de novo practice
Startups are a meaningful share of the market — in freestanding surgical centres, for instance, roughly 53% of SBA-financed projects are startups where the loan opens the business. The analysis differs substantially.
Demographic demand is established from the ground up: trade area population by age cohort, insurance coverage, income, and the prevalence of the conditions the practice treats. For dental, the relevant ratios are population per practising dentist and the local dentist-to-population trend.
Provider supply is mapped precisely. How many practising clinicians in the trade area, their apparent capacity, their acceptance of new patients, and their payer participation. A market with a favourable population-per-dentist ratio but universal open capacity is not underserved.
The ramp is the model. A de novo practice builds a patient panel over two to four years, and the projection must show the build monthly, not annually, with realistic new-patient acquisition rates and the marketing spend required to achieve them.
Working capital is central rather than incidental. A new practice has full fixed cost — lease, equipment debt, staff — from day one against a panel of zero. The period between opening and cash-flow breakeven has to be funded explicitly, and it is the most common reason de novo practices fail.
Credentialing timelines. A practice cannot bill a payer before it is credentialed with that payer, and credentialing routinely takes months. A revenue model that begins collecting in month one from plans the practice has not yet joined is wrong in a way a specialist lender will spot immediately.
Building the projection
Revenue is built from providers × clinical days × production per day × collection rate by payer. Not from a revenue target, and not from a percentage growth assumption applied to the seller's historical collections.
For an acquisition, historical collections are the anchor — but they are the seller's collections. The projection must adjust for the production the seller takes with them, the buyer's own capacity, and any change in payer participation the buyer intends.
Cost structure in clinical practice has a recognisable shape and lenders know it:
- Clinical labour including hygienists, assistants and associate compensation, which is frequently production-based and therefore variable
- Front office and administrative staffing
- Supplies and lab, which scale with production and vary by specialty mix
- Occupancy at contracted rent with escalations modelled
- Equipment finance where separate from the acquisition loan
- Insurance, including malpractice, which varies materially by specialty
- Marketing, which cannot be zero for a de novo and should not be zero for an acquisition in transition
Replacement reserves. Chairs, imaging, sterilisation, practice management systems and digital equipment all have finite lives. Where financing is USDA-guaranteed this is a regulatory requirement — Part 5001 defines coverage as EBITDA less reasonably expected replacement capital expenditures — and digital dentistry investment is precisely the kind of capital cycle that gets omitted.
Coverage is then tested through the transition period, not only at stabilisation. With debt service commonly consuming 25% to 40% of free cash flow, the months immediately following ownership transfer are where the risk sits.
Sensitivity that matters here
Generic sensitivities are not useful in this asset class. The ones that are:
Provider departure. What coverage looks like if the highest-producing associate leaves in year two.
Payer contract renegotiation. What a 10% reduction in the dominant PPO's fee schedule does.
Panel attrition on transition. Coverage at 85%, 80% and 75% of the seller's collections retained.
Buyer production shortfall. Where the buyer is a first-time owner, what happens if they produce at 85% of the seller's rate rather than matching it.
Credentialing delay, for de novo practices.
Each of these is specific, quantifiable and genuinely predictive. A lender reading them recognises an analyst who understands the asset class.
How the programmes differ
SBA 7(a). The dominant structure below $5 million, with a specialist lender community that knows this sector well. That is worth knowing: these lenders will test provider dependency and payer mix without being prompted, so the study should address both before they ask. SOP 50 10 8 sets when a third-party feasibility study is expected — including changes of ownership and businesses under two years old, which covers most practice transactions.
SBA 504. Applies where the transaction includes real estate. A practice purchasing its building alongside the practice acquisition may use both programmes, and the analysis has to support the property as well as the operation.
USDA B&I. Available in communities of 50,000 or fewer, up to $25 million, with fiscal 2026 guarantees at 85% below $5 million and 80% at or above. USDA's scope under Part 5001 Appendix A to Subpart D adds an economic and community impact dimension — and for a rural medical or dental practice, that argument is unusually strong. Roughly 65% of rural counties are primary-care shortage areas, and a practice that measurably improves access is making the case USDA is asking for.
Conventional. No prescribed scope, but practice-specific lenders often have their own requirements, and asking for the credit policy in advance is worthwhile.
In all cases the study must be prepared by an independent third party with no financial interest in the transaction — which excludes the practice broker, the seller, and the equipment vendor.
What the lender is reading for
A practice acquisition lender has financed hundreds of these. They are looking for four things.
Who produces the revenue, and are they staying? This is the first question and frequently the whole question.
What does the practice actually collect, and from whom? Gross production is not revenue. Collections by payer, net of write-offs, is.
Does the buyer have the clinical and business capacity to run it? Particularly for a first-time owner.
Does it cover through the transition, not just at stabilisation? Debt service at 25% to 40% of free cash flow leaves limited room for a slow handover.
A study that addresses those four directly, with the production and collections data to support them, will clear review. One that establishes local demographic demand for healthcare and stops there will not, however well written it is — because in the safest asset class in the programme, market demand was never the risk.
Prepared by feasibility-study-consultant.com. Market data reflects published sources at the date of writing and moves with transaction conditions. Programme requirements should be verified against current SBA and USDA guidance. Last updated: July 30, 2026.